English
Arabic
Dutch
French
German
Hindi
Italian
Russian
Spanish
Abstract :
To describe the various types of ocular posterior segment and neuro-ophthalmic manifestation associated with Human Immuno-deficiency virus (HIV) infection. And also describe the management or preventive measures associated with it. In all cases of ocular disease due to HIV, there is only one reason i.e. immune system.
A Descriptive study was done to review the articles available on PubMed, Google Scholar, Medline, Publon, Orcid, Healthstar, Science Open, Cochrane Library, Paperity and others related to the ocular complications associated with HIV infections. Peer-reviewed articles/ studies were referred to ascertain the available screening tests, preventive measures, hygiene, neuro-ophthalmic manifestation and management options for HIV patients. Some authors suggest that ocular posterior segment & neuro-ophthalmic manifestation due to HIV infection is not recovered, but few authors suggest that it can be recovered with the help of highly active antiretroviral therapy (HAART) in combination with some preventive measures and hygiene.
The Eye-care professional’s responsibility is to spread awareness about the complications related to the eye and their management or preventive measures. Ocular complications are very diverse and relatively frequent in the case of HIV infection. Commonly it is associated with a concurrent diagnosis of depression, anxiety, panic, attack and psychiatric disorders, etc. There are various management or preventive measures like regular eye examinations, follow-up of the HIV patients, following the preventive measures strategies, taking therapy properly, preventing to spread of the infection, etc.
Keywords :
CMVR, HIV, Neuro-ophthalmic manifestation, Posterior segment, Visual impairment.References :
1. Gottlieb MS, Schroff R, Schanker HM, et al. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: Evidence of a new acquired cellular immunodeficiency. N. Engl J Med. 1981;305:1425–31.
2. Masur H,Michelis MA, Green JB, et al. An outbreak of community acquired Pneumocystis carinii pneumonia: Initial manifestation of cellular immune dysfunction. N Engl J Med. 1981;305:1431–8.
3. Barre-Sinoussi F, Chermann JC. The etiologic agent of AIDS. Mt. Sinai J Med. 1986;53:598–608.
4. Safai B, Sarnagadharan MG, Groopman JE, Arnett K, et al. Sero epidemiological studies of human T-lymphotropic retrovirus type III in acquired immunodeficiency syndrome. Lancet. 1984;1:1438–40.
5. Assefa Y, Yohanness AG, Melese A. Ocular manifestations of HIV/AIDS patients in Gondar University Hospital, northwest Ethiopia. Ethiop J Health Dev. 2006;20 (3):166-169.
6. Krestelyn PG, Cunningham ET Jr. HIV/AIDS and blindness. Bull World Health Organ. 2001;79 (3):208-213.
7. Chiou SH, Liu CY, Hsu WM, et al. Ophthalmic patients with acquired immunodeficiency syndrome. J Microbiol Immunol Infect. 2000; 33 (1):45-48.
8. Chakraborty J. HIV/AIDS and ocular manifestations. J Indian Med Assoc. 1999; 97 (8): pp, 299-304.
9. Biswas J, Sudharshan S. Anterior segment manifestations of human immunodeficiency virus / acquired immune deficiency syndrome. Indian J Ophthalmol 2008;56 (5), pp:363-75.
10. Holland GN. AIDS and ophthalmology: The first quarter century. Am J Ophthalmol 2008;145:397 408.
11. Accorinti M,Pirraglia MP,Corradi R,Corsi C, Fabiani C,Pivetti Pezzi P. Changing patterns of ocular manifestations in HIV seropositive patients treated with HAART. Eur J Ophthalmol 2006;16:728 32.
12. Goldberg DE, Smithen LM,Angelilli A,Freeman WR. HIV associated retinopathy in the HAART era. Retina 2005;25:633 83.
13. Salal Khan et al. Ocular complications associated with human immuno-deficiency virus (HIV) infection and its management options: a review study; Int J Adv Res and Rev; 7(8); 2022; 1-18.
14. Holland GN. AIDS and ophthalmology: The first quarter century. Am J Ophthalmol 2008;145:397 408.
15. Accorinti M,Pirraglia MP,Corradi R,Corsi C, Fabiani C,Pivetti Pezzi P. Changing patterns of ocular manifestations in HIV seropositive patients treated with HAART. Eur J Ophthalmol 2006;16:728 32.
16. Goldberg DE, Smithen LM,Angelilli A,Freeman WR. HIV associated retinopathy in the HAART era. Retina 2005;25:633 83.
17. Sudharshan S, Kaleemunnisha S, Banu AA, Shrikrishna S, GeorgeAE, BabuBR,et al.Ocularlesions in1,000 consecutiveHIV positive patients in India:A long term study. J Ophthalmic Inflamm Infect 2013;3:2.
18. Vrabec TR. Posterior segment manifestations of HIV/AIDS. Surv Ophthalmol 2004;49:131 57.
19. Munro M, Yadavalli T, Fonteh C, Arfeen S, Lobo Chan AM. Cytomegalovirus retinitis in HIV and non HIV individuals. Microorganisms 2019;8:55.
20. Jabs DA, Ahuja A, Van Natta ML, Lyon AT, Yeh S, Danis R, et al. Long term outcomes of cytomegalovirus retinitis in the era of modern antiretroviral therapy: Results from a United States Cohort. Ophthalmology 2015;122:1452 63.
21. Kempen JH, Jabs DA, Wilson LA, Dunn JP, West SK, Tonascia JA. Risk of vision loss in patients with cytomegalovirus retinitis and the acquired immunodeficiency syndrome. Arch Ophthalmol 2003;121:466 76.
22. Kempen JH, Jabs DA, Dunn JP, West SK, Tonascia J. Retinal detachment risk in cytomegalovirus retinitis related to the acquired immunodeficiency syndrome. Arch Ophthalmol 2001;119:33 40.
23. Kempen JH, Jabs DA, Wilson LA, Dunn JP, West SK, Tonascia J. Mortality risk for patients with cytomegalovirus retinitis and acquired immune deficiency syndrome. Clin Infect Dis 2003;37:1365 73.
24. Lee JH, Agarwal A, Mahendradas P, Lee CS, Gupta V, Pavesio C, et al. Viral posterior uveitis. Surv Ophthalmol 2017;62:404 45.
25. Turner N, Strand A, Grewal DS, Cox G, Arif S, Baker AW, et al. Use of letermovir as salvage therapy for drug resistant cytomegalovirus retinitis. Antimicrob Agents Chemother 2019;63:e02337 18.
26. Otiti Sengeri J, Meenken C, van den Horn GJ, Kempen JH. Ocular immune reconstitution inflammatory syndromes. Curr Opin HIV AIDS 2008;3:432 7.
27. Singh R, Bhalekar S, Parchand S, Sharma A, Gupta V, Dogra MR, et al. Outcome of surgery in post cytomegalovirus retinal detachment: Experience before and in the era of highly active anti retroviral therapy in Indian eyes. Indian J Ophthalmol 2013;61:636 9
28. Schoenberger SD, Kim SJ, Thorne JE, Mruthyunjaya P, Yeh S, Bakri SJ, et al. Diagnosis and treatment of acute retinal necrosis:A report by the American Academy of Ophthalmology. Ophthalmology 2017;124:382 92.
29. Engstrom RE Jr, Holland GN, Margolis TP, Muccioli C, Lindley JI, Belfort R, et al. The progressive outer retinal necrosis syndrome. A variant of necrotizing herpetic retinopathy in patients with AIDS. Ophthalmology 1994;101:1488 502.
30. Cunningham ET Jr,Wong RW,Takakura A,Downes KM, Zierhut M. Necrotizing herpetic retinitis.Ocul Immunol Inflamm 2014;22:167 9.
31. Workowski KA, Bolan GA. Centers for disease control and prevention. Sexually transmitted diseases treatment guidelines, 2015 [published correction appears in MMWR Recomm Rep 2015;64:924]. MMWR Recomm Rep 2015;64:1 137.
32. Holland GN, Engstrom RE Jr, Glasgow BJ, Berger BB, Daniels SA, Sidikaro Y, et al. Ocular toxoplasmosis in patients with the acquired immunodeficiency syndrome. Am J Ophthalmol 1988;106:653 67.
33. de la Torre A, Gómez Marín J. Disease of the year 2019: Ocular toxoplasmosis in HIV infected patients. Ocul Immunol Inflamm 2020;1‐9. doi: 10.1080/09273948.2020.1735450.
34. Moshfeghi DM, Dodds EM, Couto CA, Santos CI, Nicholson DH, Lowder CY, et al. Diagnostic approaches to severe, atypical toxoplasmosis mimicking acute retinal necrosis. Ophthalmology 2004;111:716 25.
35. Mahalakshmi B, Therese KL, Madhavan HN, Biswas J. Diagnostic value of specific local antibody production and nucleic acid amplification technique nestedpolymerase chain reaction (nPCR)in clinically suspected ocular toxoplasmosis. Ocul Immunol Inflamm 2006;14:105 12.
36. Baharivand N,Mahdavifard A, Fouladi RF.Intravitreal clindamycin plus dexamethasone versus classic oral therapy in toxoplasmic retinochoroiditis: A prospective randomized clinical trial. Int Ophthalmol 2013;33:39 46.
37. Babu RB, Sudharshan S, Kumarasamy N, Therese L, Biswas J. Ocular tuberculosis in acquired immunodeficiency syndrome. Am J Ophthalmol 2006;142:413 8.
38. Rathinam SR, Lalitha P.Paradoxical worsening of ocular tuberculosis in HIVpatients after anti-retroviraltherapy.Eye (Lond) 2007;21:667 8.
39. Ganesh SK,Abraham S, Sudharshan S; Paradoxical reactions in ocular tuberculosis. J Ophthalmic Inflamm Infect 2019;9:19.
40. Walker NF, Stek C, Wasserman S, Wilkinson RJ, Meintjes G. The tuberculosis associated immune reconstitution inflammatory syndrome: Recent advances in clinical and pathogenesis research. Curr Opin HIV AIDS 2018;13:512 21.
41. Mehta S, Mansoor H, Khan S, Saranchuk P, Isaakidis P. Ocular inflammatory disease and oculartuberculosis in a cohort of patients co infected with HIV and multidrug resistant tuberculosis in Mumbai,India:A cross sectional study. BMC Infect Dis 2013;13:225.
42. Nahid P, Mase SR, Migliori GB, Sotgiu G, Bothamley GH, Brozek JL, et al. Treatment of drug resistant tuberculosis.An official ATS/CDC/ ERS/IDSA clinical practice guideline [published correction appears inAm J Respir Crit Care Med 2020;201:500 1].Am J Respir Crit Care Med 2019;200:e93 e142.
43. Lutfey M, Della Latta P,Kapur V,Palumbo LA,Gurner D, Stotzky,G, et al.Independent origin of mono rifampin resistant Mycobacterium tuberculosis in patients with AIDS. Am J Respir Crit Care Med 1996;153:837 40.
44. Masur H,Brooks JT, Benson CA,Holmes KK,Pau AK, Kaplan JE,et al. Prevention andtreatment of opportunistic infections in HIV infected adults and adolescents: Updated Guidelines from the Centers for Disease Control and Prevention, National Institutes of Health, and HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2014;58:1308 11.
45. Durnian JM, Naylor G, Saeed AM. Ocular syphilis: The return of an old acquaintance. Eye (Lond) 2004;18:440 2.
46. Lee SY, Cheng V, Rodger D, Rao N. Clinical and laboratory characteristics of ocular syphilis: A new face in the era of HIV co infection. J Ophthalmic Inflamm Infect 2015;5:56.
47. Morshed MG, Singh AE. Recent trends in the serologic diagnosis of syphilis. Clin Vaccine Immunol 2015;22:137 47.
48. Müller M, Ewert I, Hansmann F, Tiemann C, Hagedorn HJ, Solbach W, et al. Detection of Treponema pallidum in the vitreous by PCR. Br J Ophthalmol 2007;91:592 5.
49. Mansour AM. Neuro-ophthalmic findings in acquired immunodeficiency syndrome. J Clin Neuroophthalmol 1990;10: 167-74.
50. Gordon LK, Danesh Meyer H. Neuro ophthalmic manifestations of HIV infection. Ocul Immunol Inflamm 2020;1 9. doi: 10.1080/09273948.2019.1704024.
51. Ananth JV, Sudharshan S, SelvakumarA, Devaleenal BJ, Kalaivani K, Biswas J.Idiopathic intracranial hypertension associated with anaemia, secondary to antiretroviral drug in a human immunodeficiency virus positive patient. Indian J Ophthalmol 2018;66:168 9.
52. Jeyaraman VA, Sudharshan S, Selvakumar A, Bassi S, Noronha OV, Selvamuthu P, et al. Isolated cortical blindness without simultaneous neurological involvement in progressive multifocal leukoencephalopathy in a patient with human immune deficiency virus infection. J Ophthalmic Inflamm Infect 2013;3:3.
53. Curi AL, Machado DO, Heringer G, Campos WR, Orefice F. Ocular manifestation of cat scratch disease in HIV positive patients. Am J Ophthalmol 2006;141:400 1.
54. Whitcup SM, Butler KM, Caruso R, de Smet MD, Rubin B, Husson RN,et al.Retinaltoxicity in human immunodeficiency virus infected children treated with 2’,3’ dideoxyinosine. Am J Ophthalmol 1992;113:1 7.
55. Sen P, Sudharshan S, Banerjee A, Dhami A. Clinical and electrophysiological characteristics of Efavirenz induced macular toxicity. GMS Ophthalmol Cases 2020;10:Doc08.
56. Papavasileiou E, Younis S, Zygoura V, Quijano C, Jackson TL. Ritonavir associated toxicity mimicking retinitis pigmentosa in an HIV infected patient on highly active antiretroviral therapy. Retin Cases Brief Rep 2017;11:306 9
57. Testi I, Agarwal A, Agrawal R, Mahajan S, Marchese A, Miserocchi E, et al. Drug induced uveitis in HIV patients with ocular opportunistic infections. Ocul Immunol Inflamm 2019;1–7. doi: 10.1080/09273948.2019.1691240.
58. Freeman WR, Gross JG, Labelle J, Oteken K, Katz B, Wiley CA. Pneumocystis carinii choroidopathy: A new clinical entity. Arch Ophthalmol 1989;107:863-7.
59. Shami MJ, Freeman W, Friedberg D, Siderides E, Listhaus A, Ai E. A multicenter study of pneumocystis choroidopathy. Am J Ophthalmol 1991;112:15-22.
60. Muccioli C, Belfort R, Neves R, Rao N. Limbal and choroidal Cryptococcus infection in the acquired immunodeficiency syndrome. Am J Ophthalmol 1995;120:539-40.
61. Bergemann A, Karstaedt AS. The spectrum of meningitis in a population with high prevalence of HIV disease. Qjm. 1996;89 (7):499–504. doi:10.1093/qjmed/89.7.499.
62. Espino Barros Palau A, Morgan ML, Foroozan R, Lee AG. Neuroophthalmic presentations and treatment of cryptococcal meningitis-related increased intracranial pressure. Can J Ophthalmol. 2014;49(5):473–477.
doi:10.1016/j.jcjo.2014.06.012.
63. Merkler AE, Gaines N, Baradaran H, et al. Direct invasion of the optic nerves, chiasm, and tracts by cryptococcus neoformans in an immunocompetent host. Neurohospitalist. 2015;5(4):217–222. doi:10.1177/1941874415569072.
64. Merkler AE, Reynolds AS, Gialdini G, et al. Neurological complications after tuberculous meningitis in a multi-state cohort in the United States. J Neurol Sci. 2017;375:460–463. doi:10.1016/j. jns.2017.02.051.
65. Moodley A, Rae W, Bhigjee A. Visual loss in HIV-associated cryptococcal meningitis: A case series and review of the mechanisms involved. South Afr J HIV Med. 2015;16(1):305. doi:10.4102/ sajhivmed.v16i1.305.
66. Veltman JA, Bristow CC, Klausner JD. Meningitis in HIV-positive patients in sub-Saharan Africa: a review. J Int AIDS Soc. 2014;17:19184. doi:10.7448/IAS.17.1.19184
67. Golnik KC, Newman SA, Wispelway B. Cryptococcal optic neuropathy in the acquired immune deficiency syndrome. J Clin Neuroophthalmol. 1991;11:96–103.
68. Rajasingham R, Rhein J, Klammer K, et al. Epidemiology of meningitis in an HIV-infected Ugandan cohort. Am J Trop Med Hyg. 2015;92(2):274–279. doi:10.4269/ajtmh.14-0452.
69. Moodley A, Rae W, Bhigjee A, et al. Early clinical and subclinical visual evoked potential and humphrey’s visual field defects in cryptococcal meningitis. PLoS One. 2012;7(12):e52895. doi:10.1371/journal.pone.0052895.
70. Benjamin LA, Kelly M, Cohen D, et al. Detection of herpes viruses in the cerebrospinal fluid of adults with suspected viral meningitis in Malawi. Infection. 2013;41(1):27–31. doi:10.1007/s15010-012- 0292-z.
71. Franco-Paredes C, Bellehemeur T, Merchant A, Sanghi P, DiazGranados C, Rimland D. Aseptic meningitis and optic neuritis preceding varicella-zoster progressive outer retinal necrosis in a patient with AIDS. Aids. 2002;16(7):1045–1049. doi:10.1097/ 00002030-200205030-00011.
72. Goldberg DE, Smithen LM, Angelilli A, Freeman WR. HIVassociated retinopathy in the HAART era. Retina. 2005;25 (5):633–649. quiz 682-633. doi:10.1097/00006982-200507000- 00015.
73. Furrer H, Barloggio A, Egger M, Garweg JG. Retinal microangiopathy in human immunodeficiency virus infection is related to higher human immunodeficiency virus-1 load in plasma. Ophthalmology. 2003;110(2):432–436. doi:10.1016/S0161-6420(02) 01750-5.
74. Pivetti-Pezzi P, Accorinti M, Ciapparoni V, Vullo V, Aiuti F. Antiretroviral therapy and HIV-related retinal microangiopathy. Aids. 1997;11(15):1890–1891. doi:10.1097/ 00002030-199715000-00019.
75. Iwasaki Y, Yamamoto N, Kawaguchi T, et al. Human immunodeficiency virus-related retinal microangiopathy and systemic cytomegalovirus disease association. Jpn J Ophthalmol. 2013;57 (4):372–378. doi:10.1007/s10384-013-0247-7.
76. Nishijima T, Yashiro S, Teruya K, et al. Routine eye screening by an ophthalmologist is clinically useful for HIV-1-infected patients with CD4 count less than 200/μL. PLoS One. 2015;10(9):e0136747. doi:10.1371/journal.pone.0136747.
77. Dadgostar H, Holland GN, Huang X, et al. Hemorheologic abnormalities associated with HIV infection: in vivo assessment of retinal microvascular blood flow. Invest Ophthalmol Vis Sci. 2006;47(9):3933–3938. doi:10.1167/iovs.06-0138.
78. Jabs DA, Drye L, Van Natta ML, Thorne JE, Holland GN. Incidence and long-term outcomes of the human immunodeficiency virus neuroretinal disorder in patients with AIDS. Ophthalmology. 2015;122(4):760–768. doi:10.1016/j. ophtha.2014.11.009.
79. Wang HH, Chung YM, Lin YC, Hu HC, Wong WW. Rifabutin induced hypopyon uveitis in patients with acquired immunodeficiency syndrome infected with mycobacterium avium complex. J Chin Med Assoc. 2007;70(3):136–139. doi:10.1016/S1726- 4901(09)70345-4.
80. Riva A, Invernizzi A, Resnati C, Micheli V, Cattaneo D, Gervasoni C. Elvitegravir/cobicistat-associated toxic optical neuropathy in an HIV-infected patient: a call for caution? Antivir Ther. 2017;22(5):453–455. doi:10.3851/IMP3058.
81. Demirkaya N, Wit F, Schlingemann R, Verbraak F. Neuroretinal degeneration in HIV patients without opportunistic ocular infections in the cART Era. AIDS Patient Care STDS. 2015;29 (10):519–532. doi:10.1089/apc.2015.0091.
82. Gellrich MM, Kade G, Gerling J, Bach M, Hansen LL. Pattern, flicker, and flash electroretinography in human immunodeficiency virus infection: a longitudinal study. Ger J Ophthalmol. 1996;5 (1):16–22.
83. Mwanza JC, Nyamabo LK, Tylleskar T, Plant GT. Neuro-ophthalmological disorders in HIV infected subjects with neurological manifestations. Br J Ophthalmol. 2004;88(11):1455–1459. doi:10.1136/bjo.2004.044289.
84. Currie J, Benson E, Ramsden B, Perdices M, Cooper D. Eye movement abnormalities as a predictor of the acquired immunodeficiency syndrome dementia complex. Arch Neurol. 1988;45 (9):949–953.
doi:10.1001/archneur.1988.00520330027006.
85. Johnston JL, Miller JD, Nath A. Ocular motor dysfunction in HIV-1-infected subjects: a quantitative oculographic analysis. Neurology. 1996;46(2):451–457. doi:10.1212/WNL.46.2.451.
86. Feroze KB, Wang J. Ocular manifestations of HIV. In: StatPearls. Treasure Island (FL): StatPearls Publishing StatPearls Publishing LLC; 2019.
87. Wells CD, Moodley AA. HIV-associated cavernous sinus disease. South Afr J HIV Med. 2019;20(1):862. doi:10.4102/sajhivmed. v20i1.862.
88. Maclean H, Dhillon B. Pupil cycle time and human immunodeficiency virus (HIV) infection. Eye (Lond). 1993;7(Pt 6):785–786. doi:10.1038/eye.1993.184.
